Onderneming MaxCyte, Inc. Nasdaq
Aandelen
MXCT
US57777K1060
Geavanceerde medische apparatuur & technologie
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
4 USD | +0,50% |
|
-3,85% | -14,89% |
11/06 | MaxCyte CEO Maher Masoud koopt 100.000 aandelen | AN |
11/06 | Maxcyte Insider kocht aandelen ter waarde van $489.066, volgens een recent SEC-document | MT |
Vakgebied
Aantal werknemers: 143
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Cell Therapy
55,3
%
| 31 | 69,0 % | 23 | 55,3 % | -25,26% |
Program-related
27,8
%
| 5 | 10,4 % | 11 | 27,8 % | +148,38% |
Drug Discovery
16,9
%
| 9 | 20,6 % | 7 | 16,9 % | -23,14% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 44 | 100,0 % | 41 | 100,0 % | -6,72% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Maher Masoud
CEO | Chief Executive Officer | 49 | - |
Douglas Swirsky
DFI | Director of Finance/CFO | 54 | 27-03-23 |
James Brady
CTO | Chief Tech/Sci/R&D Officer | - | - |
Ron Holtz
ADM | Chief Administrative Officer | 66 | 01-01-05 |
Corporate Officer/Principal | - | 21-08-23 | |
Gene Zhu
LAW | General Counsel | - | - |
Jill Mayer
HRO | Human Resources Officer | - | 01-01-18 |
Thomas Ross
SAM | Sales & Marketing | 63 | 15-10-14 |
Steven Nardi
PRN | Corporate Officer/Principal | - | 13-10-20 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Patrick Balthrop
BRD | Director/Board Member | 67 | 01-12-22 |
Art Mandell
BRD | Director/Board Member | 71 | 01-05-06 |
Will Brooke
BRD | Director/Board Member | 68 | 01-03-04 |
Stanley Erck
BRD | Director/Board Member | 76 | 01-01-05 |
Ron Holtz
ADM | Chief Administrative Officer | 66 | 01-01-05 |
John Johnston
BRD | Director/Board Member | 65 | 01-01-16 |
Richard Douglas
CHM | Chairman | 71 | 12-02-18 |
Yasir Al-Wakeel
BRD | Director/Board Member | 42 | 15-06-21 |
Rekha Hemrajani
BRD | Director/Board Member | 54 | 15-06-21 |
Maher Masoud
CEO | Chief Executive Officer | 49 | - |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 104 544 289 | 97 857 767 ( 93,60 %) | 0 | 93,60 % |
Bedrijfsgegevens
![Adres MaxCyte, Inc.(MXCT)](https://cdn.zonebourse.com/static/address/120797722.png)
Sector
Verkoop per activiteit
![Consensus](/images/consensus_flch.gif)
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+3,77% | 210 mld. | |
+8,83% | 186 mld. | |
+31,94% | 158 mld. | |
+33,19% | 113 mld. | |
+5,25% | 66,13 mld. | |
+22,41% | 56,25 mld. | |
+1,34% | 49 mld. | |
-5,92% | 38,16 mld. | |
+1,94% | 35,98 mld. |
- Beurs
- Aandelen
- Koers MXCT
- Koers MXCT
- Onderneming MaxCyte, Inc.